Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 5
2008 3
2009 4
2010 7
2011 5
2012 8
2013 12
2014 17
2015 15
2016 17
2017 20
2018 25
2019 25
2020 38
2021 37
2022 53
2023 53
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bingqing li (62 results)?
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. Among authors: li b. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Gärtner J, et al. Among authors: li b. Mult Scler. 2022 Sep;28(10):1562-1575. doi: 10.1177/13524585221078825. Epub 2022 Mar 10. Mult Scler. 2022. PMID: 35266417 Free PMC article. Clinical Trial.
Engineered organoids for biomedical applications.
Roberto de Barros N, Wang C, Maity S, Peirsman A, Nasiri R, Herland A, Ermis M, Kawakita S, Gregatti Carvalho B, Hosseinzadeh Kouchehbaghi N, Donizetti Herculano R, Tirpáková Z, Mohammad Hossein Dabiri S, Lucas Tanaka J, Falcone N, Choroomi A, Chen R, Huang S, Zisblatt E, Huang Y, Rashad A, Khorsandi D, Gangrade A, Voskanian L, Zhu Y, Li B, Akbari M, Lee J, Remzi Dokmeci M, Kim HJ, Khademhosseini A. Roberto de Barros N, et al. Among authors: li b. Adv Drug Deliv Rev. 2023 Dec;203:115142. doi: 10.1016/j.addr.2023.115142. Epub 2023 Nov 13. Adv Drug Deliv Rev. 2023. PMID: 37967768 Review.
Additively manufactured metallic biomaterials.
Davoodi E, Montazerian H, Mirhakimi AS, Zhianmanesh M, Ibhadode O, Shahabad SI, Esmaeilizadeh R, Sarikhani E, Toorandaz S, Sarabi SA, Nasiri R, Zhu Y, Kadkhodapour J, Li B, Khademhosseini A, Toyserkani E. Davoodi E, et al. Among authors: li b. Bioact Mater. 2021 Dec 30;15:214-249. doi: 10.1016/j.bioactmat.2021.12.027. eCollection 2022 Sep. Bioact Mater. 2021. PMID: 35386359 Free PMC article. Review.
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Lublin F, et al. Among authors: li b. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Lancet. 2016. PMID: 26827074 Free article. Clinical Trial.
327 results